Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Microporous microparticles designed as stable immunoadsorbents.

N Ubrich1, C Rivat, C Vigneron

  • 1Laboratoire de Pharmacie Galénique et Biopharmacie, Faculté des Sciences Pharmaceutiques et Biologiques, 5, rue Albert Lebrun B.P. 403, 54001 Nancy-Cedex, France. ubrich@pharma.u-nancy.fr

Biotechnology and Bioengineering
|April 1, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Causes, management, and prognosis of severe gastrointestinal bleedings in critically ill patients with pancreatic cancer: A retrospective multicenter study.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2024
Same author

Neurological outcome of cardiac arrest patients in mountain areas: An analysis of the Northern French Alps Emergency Network.

The American journal of emergency medicine·2024
Same author

Author Correction: Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.

Nature medicine·2022
Same author

[Prognostic factors of acute radiodermatitis in breast cancer after adjuvant radiotherapy treated with RT3D or IMRT].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2022
Same author

Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.

Nature medicine·2022
Same author

Angioedema associated with thrombolysis for ischemic stroke: analysis of a case-control study.

Journal of internal medicine·2019
Same journal

Microbial Hydrolysates as Amino Acid Source in Cell Culture Media for Cellular Agriculture.

Biotechnology and bioengineering·2026
Same journal

LLM-Guided Parameter Optimization for Mechanistic CHO Cell Bioreactor Models.

Biotechnology and bioengineering·2026
Same journal

Three-Dimensional-Printed Polylactic Acid Scaffolds Coated With a Paeonol-Incorporated Gelatin/Bioactive Glass Composite Layer for Enhanced Osteogenic Performance.

Biotechnology and bioengineering·2026
Same journal

Recent Progress in Antimicrobial Peptides (AMPs) Towards Enhanced Selectivity and Reduced Cytotoxicity by Molecular Engineering.

Biotechnology and bioengineering·2026
Same journal

mZVI-Enhanced Mixed Nitrogen Removal in Klebsiella oxytoca via Coordinated Electron Transfer and Metabolic Reprogramming.

Biotechnology and bioengineering·2026
Same journal

Growth Model for Continuous Culture of a Hydrogen-Oxidizing Bacterium, Hydrogenophilus thermoluteolus Strain TH-1.

Biotechnology and bioengineering·2026
See all related articles

A novel immunoadsorbent using encapsulated antibodies effectively removes excess apolipoprotein B in familial hypercholesterolemia. This stable and efficient method offers a promising therapeutic approach for managing high cholesterol levels.

Area of Science:

  • Biochemistry
  • Immunology
  • Materials Science

Background:

  • Familial hypercholesterolemia is a genetic disorder characterized by high levels of apolipoprotein B (apoB) in the blood.
  • Excess apoB contributes to atherosclerosis and cardiovascular disease.
  • Current treatments may not be sufficient for all patients, necessitating alternative therapeutic strategies.

Purpose of the Study:

  • To develop a novel solid-phase immunoadsorbent for the selective removal of apoB from patient plasma.
  • To evaluate the adsorption capacity and stability of the developed immunoadsorbent.
  • To establish a model system for using microparticles as immunoadsorbents for other proteins.

Main Methods:

  • Development of a solid-phase immunoadsorbent using encapsulated goat anti-apoB polyclonal antibodies crosslinked with glutaraldehyde.

Related Experiment Videos

  • Preparation of a comparative immunoadsorbent using Sepharose CL-4B activated with cyanogen bromide.
  • Assessment of adsorption capacity and stability under various chemical and biochemical conditions.

    • Main Results:

    • The novel encapsulated immunoadsorbent demonstrated optimal adsorption capacity for apoB.
    • The immunoadsorbent exhibited enhanced stability compared to the classical Sepharose-based adsorbent.
    • The microparticle-based approach proved effective and versatile for protein removal.

    Conclusions:

    • Encapsulated, crosslinked antibodies offer a superior immunoadsorbent for apoB removal in familial hypercholesterolemia.
    • This technology provides a stable and efficient method for immunoaffinity depletion of excess apoB.
    • The microparticle immunoadsorbent system serves as a valuable model for broader applications in protein removal therapies.